KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 6 years of Long-Term Investments data on record, last reported at $5.7 billion in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 11.83% year-over-year to $5.7 billion; the TTM value through Dec 2025 reached $5.7 billion, up 11.83%, while the annual FY2025 figure was $5.7 billion, 11.83% up from the prior year.
  • Long-Term Investments reached $5.7 billion in Q4 2025 per VRTX's latest filing, roughly flat from $5.7 billion in the prior quarter.
  • Across five years, Long-Term Investments topped out at $5.7 billion in Q3 2025 and bottomed at $112.2 million in Q4 2022.
  • Average Long-Term Investments over 4 years is $3.4 billion, with a median of $4.4 billion recorded in 2024.
  • Peak YoY movement for Long-Term Investments: skyrocketed 2126.2% in 2023, then increased 11.83% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $112.2 million in 2022, then surged by 2126.2% to $2.5 billion in 2023, then soared by 104.5% to $5.1 billion in 2024, then rose by 11.83% to $5.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $5.7 billion in Q4 2025, $5.7 billion in Q3 2025, and $5.2 billion in Q1 2025.